{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:10Z","timestamp":1786986850494,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clml.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:10:07Z","timestamp":1647691807000},"page":"e685-e690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World"],"prefix":"10.1016","volume":"22","author":[{"given":"Charanpreet","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Panakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreejesh","family":"Sreedharanunni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jandial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-8491","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.03.005_bib0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","article-title":"Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex and geography","volume":"59","author":"Bora","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clml.2022.03.005_bib0002","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.005_bib0003","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.03.005_bib0004","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk-stratification and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.03.005_bib0005","article-title":"The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells","author":"Panakkal","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2022.03.005_bib0006","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.03.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2021.1948032","article-title":"At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China","author":"Shen","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.03.005_bib0008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.03.005_bib0009","article-title":"Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance","volume":"10","author":"Baysal","year":"2020","journal-title":"Scientific Rep"},{"key":"10.1016\/j.clml.2022.03.005_bib0010","first-page":"105","article-title":"The frequency and clinico-hematological characteristics of gain(1q21) positive myeloma in an Indian cohort","author":"Panakkal","year":"2021","journal-title":"Leukemia Res"},{"key":"10.1016\/j.clml.2022.03.005_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-018-0163-7","article-title":"Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome","volume":"8","author":"Paquin","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.03.005_bib0012","doi-asserted-by":"crossref","unstructured":"Yanamandra U, Sharma R, Shankar S, et\u00a0al. Survival outcomes of newly diagnosed multiple myeloma at a tertiary care center in North India (IMAGe: 001A study). 2021:704-715. doi:10.1200\/GO.20.00625","DOI":"10.1200\/GO.20.00625"},{"key":"10.1016\/j.clml.2022.03.005_bib0013","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12288-017-0876-y","article-title":"Autologous stem cell transplantation for multiple myeloma: single centre experience from North India","volume":"34","author":"Malhotra","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2022.03.005_bib0014","first-page":"912","article-title":"Adverse effects of double-hit combining ISS-\u2162 stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma","volume":"40","author":"Liu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2022.03.005_bib0015","first-page":"918","article-title":"Clinical prognosis analysis of patients with \u201cdouble hit\u201d multiple myeloma","volume":"4","author":"Luo","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"7","key":"10.1016\/j.clml.2022.03.005_bib0016","first-page":"392","article-title":"Early mortality in multiple myeloma: experiences from a single institution","volume":"21","author":"Chen","year":"2016","journal-title":"Hematol (Amsterdam, Netherlands)"},{"issue":"7","key":"10.1016\/j.clml.2022.03.005_bib0017","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/leu.2015.33","article-title":"Early mortality in multiple myeloma","volume":"29","author":"Costa","year":"2015","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.03.005_bib0018","article-title":"Trends in early mortality from multiple myeloma (MM): a population-based analysis","volume":"134","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.03.005_bib0019","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.03.005_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:48Z","timestamp":1761871128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2152265022000866"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}